| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 433 | 2023 | 1268 | 23.770 |
Why?
|
| Tacrolimus | 194 | 2021 | 373 | 9.730 |
Why?
|
| Immunosuppressive Agents | 176 | 2021 | 977 | 9.030 |
Why?
|
| Graft Rejection | 219 | 2021 | 1065 | 8.120 |
Why?
|
| Graft Survival | 210 | 2023 | 884 | 7.500 |
Why?
|
| Organ Transplantation | 50 | 2019 | 265 | 4.060 |
Why?
|
| Kidney Transplantation | 95 | 2023 | 849 | 3.590 |
Why?
|
| Liver Neoplasms | 45 | 2019 | 736 | 3.370 |
Why?
|
| Postoperative Complications | 90 | 2018 | 2207 | 3.170 |
Why?
|
| Tissue Donors | 61 | 2018 | 463 | 2.880 |
Why?
|
| Liver Failure | 23 | 2017 | 78 | 2.840 |
Why?
|
| Liver | 86 | 2018 | 1230 | 2.680 |
Why?
|
| Hepatectomy | 23 | 2019 | 166 | 2.660 |
Why?
|
| Bone Marrow Transplantation | 52 | 2004 | 286 | 2.460 |
Why?
|
| Islets of Langerhans Transplantation | 35 | 2019 | 225 | 2.330 |
Why?
|
| Heart Transplantation | 84 | 2019 | 705 | 2.210 |
Why?
|
| Transplantation, Homologous | 112 | 2017 | 996 | 2.110 |
Why?
|
| Humans | 573 | 2023 | 86643 | 2.060 |
Why?
|
| Transplantation, Heterologous | 50 | 2004 | 363 | 1.940 |
Why?
|
| Carcinoma, Hepatocellular | 25 | 2017 | 384 | 1.930 |
Why?
|
| Hepatic Artery | 15 | 2016 | 83 | 1.920 |
Why?
|
| Hepatitis C | 20 | 2014 | 208 | 1.890 |
Why?
|
| Adult | 304 | 2020 | 25648 | 1.850 |
Why?
|
| Tissue and Organ Procurement | 22 | 2023 | 311 | 1.830 |
Why?
|
| Male | 391 | 2019 | 40965 | 1.830 |
Why?
|
| Dendritic Cells | 46 | 2014 | 425 | 1.820 |
Why?
|
| Mycophenolic Acid | 18 | 2016 | 87 | 1.750 |
Why?
|
| Middle Aged | 254 | 2019 | 25028 | 1.720 |
Why?
|
| Pancreas Transplantation | 23 | 2007 | 103 | 1.670 |
Why?
|
| Treatment Outcome | 109 | 2023 | 7993 | 1.540 |
Why?
|
| Female | 305 | 2021 | 44532 | 1.540 |
Why?
|
| Time Factors | 122 | 2019 | 5210 | 1.500 |
Why?
|
| Kidney | 21 | 2023 | 1241 | 1.480 |
Why?
|
| Lymphoproliferative Disorders | 25 | 2008 | 107 | 1.470 |
Why?
|
| Immune Tolerance | 26 | 2017 | 337 | 1.460 |
Why?
|
| Calcineurin Inhibitors | 4 | 2021 | 54 | 1.460 |
Why?
|
| Transplantation Immunology | 23 | 2015 | 84 | 1.440 |
Why?
|
| Hepatitis B | 11 | 2009 | 74 | 1.380 |
Why?
|
| Liver Diseases | 24 | 2018 | 238 | 1.330 |
Why?
|
| HIV Infections | 13 | 2017 | 772 | 1.320 |
Why?
|
| T-Lymphocytes | 54 | 2018 | 1195 | 1.300 |
Why?
|
| Transplantation Chimera | 27 | 2004 | 80 | 1.270 |
Why?
|
| Survival Rate | 73 | 2016 | 1863 | 1.240 |
Why?
|
| Follow-Up Studies | 96 | 2019 | 3640 | 1.200 |
Why?
|
| Organ Preservation | 12 | 2017 | 83 | 1.180 |
Why?
|
| Intestines | 21 | 2017 | 411 | 1.170 |
Why?
|
| Living Donors | 11 | 2023 | 339 | 1.110 |
Why?
|
| Patient Selection | 22 | 2020 | 685 | 1.100 |
Why?
|
| Intestine, Small | 31 | 2003 | 303 | 1.090 |
Why?
|
| Liver Cirrhosis | 21 | 2016 | 297 | 1.070 |
Why?
|
| Gastroenterology | 3 | 2017 | 134 | 1.040 |
Why?
|
| Transplantation Tolerance | 10 | 2017 | 130 | 1.020 |
Why?
|
| Prednisone | 34 | 2005 | 258 | 1.000 |
Why?
|
| Animals | 222 | 2021 | 26582 | 0.990 |
Why?
|
| Retrospective Studies | 105 | 2023 | 8489 | 0.960 |
Why?
|
| Laparoscopy | 11 | 2019 | 754 | 0.960 |
Why?
|
| Risk Factors | 52 | 2023 | 5417 | 0.940 |
Why?
|
| Cyclosporine | 33 | 2006 | 234 | 0.940 |
Why?
|
| Sirolimus | 13 | 2014 | 169 | 0.910 |
Why?
|
| Survival Analysis | 52 | 2017 | 1538 | 0.900 |
Why?
|
| Aged | 119 | 2019 | 18415 | 0.890 |
Why?
|
| Drug Therapy, Combination | 44 | 2017 | 894 | 0.890 |
Why?
|
| Everolimus | 3 | 2018 | 40 | 0.890 |
Why?
|
| End Stage Liver Disease | 7 | 2018 | 61 | 0.870 |
Why?
|
| Diabetes Mellitus, Type 1 | 22 | 2019 | 567 | 0.860 |
Why?
|
| Hepatic Stellate Cells | 8 | 2016 | 10 | 0.830 |
Why?
|
| Constriction, Pathologic | 4 | 2011 | 213 | 0.820 |
Why?
|
| Incidence | 44 | 2019 | 1577 | 0.820 |
Why?
|
| Child | 101 | 2023 | 6927 | 0.810 |
Why?
|
| Facial Transplantation | 3 | 2010 | 14 | 0.810 |
Why?
|
| Reoperation | 41 | 2018 | 597 | 0.800 |
Why?
|
| History, 20th Century | 9 | 2017 | 312 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 28 | 2013 | 1376 | 0.800 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2018 | 212 | 0.780 |
Why?
|
| Short Bowel Syndrome | 5 | 2017 | 37 | 0.770 |
Why?
|
| Transplantation | 7 | 2012 | 39 | 0.760 |
Why?
|
| Mice, Inbred C3H | 60 | 2009 | 370 | 0.760 |
Why?
|
| Rats, Inbred Lew | 58 | 2002 | 186 | 0.760 |
Why?
|
| T-Lymphocytes, Cytotoxic | 29 | 2013 | 315 | 0.750 |
Why?
|
| Swine | 13 | 2014 | 555 | 0.740 |
Why?
|
| Graft vs Host Disease | 26 | 2001 | 365 | 0.740 |
Why?
|
| Mice | 116 | 2021 | 11352 | 0.740 |
Why?
|
| Liver Diseases, Alcoholic | 4 | 2020 | 24 | 0.740 |
Why?
|
| Prospective Studies | 47 | 2018 | 4213 | 0.730 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2009 | 64 | 0.730 |
Why?
|
| Pancreas | 6 | 2018 | 239 | 0.720 |
Why?
|
| Histocompatibility Testing | 19 | 2015 | 154 | 0.720 |
Why?
|
| Hepatitis C, Chronic | 9 | 2017 | 126 | 0.720 |
Why?
|
| History, 21st Century | 7 | 2017 | 175 | 0.720 |
Why?
|
| Facial Injuries | 2 | 2010 | 19 | 0.720 |
Why?
|
| Adolescent | 91 | 2019 | 8981 | 0.710 |
Why?
|
| Intestinal Diseases | 9 | 2016 | 79 | 0.700 |
Why?
|
| Mice, Inbred C57BL | 64 | 2018 | 3092 | 0.700 |
Why?
|
| Child, Preschool | 64 | 2016 | 3612 | 0.680 |
Why?
|
| Antigens, CD | 27 | 2016 | 458 | 0.680 |
Why?
|
| Portal Vein | 15 | 2014 | 120 | 0.660 |
Why?
|
| Adenosine | 5 | 2016 | 225 | 0.640 |
Why?
|
| Ischemia | 9 | 2010 | 243 | 0.630 |
Why?
|
| Biliary Tract Diseases | 5 | 2007 | 34 | 0.630 |
Why?
|
| Organ Preservation Solutions | 4 | 2006 | 28 | 0.620 |
Why?
|
| Cause of Death | 16 | 2006 | 277 | 0.610 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 160 | 0.610 |
Why?
|
| Portacaval Shunt, Surgical | 3 | 2009 | 9 | 0.610 |
Why?
|
| Lymphocyte Activation | 39 | 2016 | 728 | 0.600 |
Why?
|
| Antiviral Agents | 16 | 2014 | 510 | 0.600 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2017 | 860 | 0.600 |
Why?
|
| Liver Circulation | 10 | 2018 | 30 | 0.600 |
Why?
|
| Rats | 79 | 2003 | 3990 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 26 | 1996 | 746 | 0.590 |
Why?
|
| Myeloid Cells | 6 | 2014 | 98 | 0.590 |
Why?
|
| Reperfusion Injury | 7 | 2016 | 131 | 0.590 |
Why?
|
| Death | 5 | 2015 | 73 | 0.580 |
Why?
|
| Kidney Diseases | 3 | 2018 | 418 | 0.580 |
Why?
|
| Hepatocytes | 7 | 2014 | 127 | 0.580 |
Why?
|
| Antilymphocyte Serum | 12 | 2021 | 71 | 0.580 |
Why?
|
| Skin Transplantation | 14 | 1999 | 172 | 0.580 |
Why?
|
| Histocompatibility Antigens Class II | 15 | 1999 | 158 | 0.580 |
Why?
|
| Ohio | 12 | 2017 | 37 | 0.560 |
Why?
|
| Waiting Lists | 8 | 2012 | 175 | 0.550 |
Why?
|
| Vena Cava, Inferior | 7 | 2018 | 143 | 0.530 |
Why?
|
| Bile Ducts | 7 | 2014 | 59 | 0.520 |
Why?
|
| Cohort Studies | 19 | 2018 | 2767 | 0.520 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2015 | 40 | 0.520 |
Why?
|
| Pancreatectomy | 5 | 2019 | 148 | 0.520 |
Why?
|
| Apoptosis | 23 | 2013 | 1683 | 0.520 |
Why?
|
| Biopsy | 20 | 2018 | 1163 | 0.510 |
Why?
|
| Hepatic Veins | 3 | 2009 | 27 | 0.510 |
Why?
|
| Risk Assessment | 16 | 2017 | 2261 | 0.510 |
Why?
|
| Membrane Glycoproteins | 17 | 2009 | 428 | 0.510 |
Why?
|
| Histocompatibility Antigens Class I | 11 | 2001 | 203 | 0.510 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2017 | 425 | 0.510 |
Why?
|
| Cadaver | 18 | 2010 | 185 | 0.510 |
Why?
|
| Guideline Adherence | 1 | 2016 | 223 | 0.510 |
Why?
|
| HLA Antigens | 15 | 2015 | 232 | 0.500 |
Why?
|
| HIV Protease Inhibitors | 3 | 2003 | 21 | 0.500 |
Why?
|
| Stromal Cells | 3 | 2011 | 143 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 1036 | 0.490 |
Why?
|
| Isoantibodies | 10 | 2018 | 114 | 0.490 |
Why?
|
| Cholangitis, Sclerosing | 4 | 2012 | 52 | 0.490 |
Why?
|
| B-Lymphocytes | 12 | 2016 | 724 | 0.480 |
Why?
|
| Islets of Langerhans | 12 | 2019 | 544 | 0.480 |
Why?
|
| Cholestasis | 2 | 2023 | 47 | 0.480 |
Why?
|
| Blood Glucose | 14 | 2019 | 873 | 0.480 |
Why?
|
| B7-H1 Antigen | 6 | 2017 | 250 | 0.480 |
Why?
|
| Myeloid-Derived Suppressor Cells | 3 | 2018 | 17 | 0.470 |
Why?
|
| Colectomy | 4 | 2015 | 167 | 0.470 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 2011 | 29 | 0.470 |
Why?
|
| Cricetinae | 38 | 2001 | 560 | 0.470 |
Why?
|
| United States | 26 | 2023 | 6672 | 0.460 |
Why?
|
| Biomedical Research | 2 | 2017 | 376 | 0.460 |
Why?
|
| Mice, Inbred BALB C | 33 | 2021 | 1047 | 0.460 |
Why?
|
| Herpesvirus 4, Human | 13 | 2005 | 114 | 0.450 |
Why?
|
| Immunoglobulin M | 14 | 2016 | 154 | 0.440 |
Why?
|
| Immunoconjugates | 10 | 2002 | 106 | 0.440 |
Why?
|
| Biliary Atresia | 3 | 2023 | 22 | 0.430 |
Why?
|
| Immunotherapy | 5 | 2017 | 629 | 0.430 |
Why?
|
| Lymphocytes | 15 | 2003 | 464 | 0.430 |
Why?
|
| Antigens, Differentiation | 11 | 2003 | 141 | 0.430 |
Why?
|
| Cytokines | 20 | 2021 | 776 | 0.430 |
Why?
|
| Pregnancy Outcome | 2 | 2004 | 247 | 0.420 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2011 | 26 | 0.420 |
Why?
|
| Mycoses | 5 | 2002 | 46 | 0.420 |
Why?
|
| B7-1 Antigen | 11 | 2013 | 75 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 582 | 0.410 |
Why?
|
| Choledochostomy | 1 | 2011 | 8 | 0.410 |
Why?
|
| Predictive Value of Tests | 15 | 2018 | 1673 | 0.410 |
Why?
|
| Interferon-gamma | 18 | 2015 | 444 | 0.410 |
Why?
|
| Thrombosis | 7 | 2006 | 296 | 0.410 |
Why?
|
| Splenectomy | 9 | 2001 | 82 | 0.410 |
Why?
|
| Immunoglobulin G | 18 | 2016 | 456 | 0.400 |
Why?
|
| Bile Duct Diseases | 3 | 2011 | 22 | 0.400 |
Why?
|
| Insulin | 11 | 2019 | 1160 | 0.400 |
Why?
|
| Prognosis | 26 | 2018 | 3679 | 0.400 |
Why?
|
| Interleukin-2 | 15 | 2008 | 249 | 0.400 |
Why?
|
| Antibodies, Neoplasm | 6 | 2006 | 84 | 0.400 |
Why?
|
| Immunization, Passive | 4 | 2000 | 71 | 0.390 |
Why?
|
| Cells, Cultured | 38 | 2018 | 2818 | 0.390 |
Why?
|
| Colorectal Neoplasms | 7 | 2018 | 938 | 0.390 |
Why?
|
| Lymphocyte Culture Test, Mixed | 26 | 2010 | 74 | 0.390 |
Why?
|
| Anastomosis, Surgical | 8 | 2015 | 267 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2018 | 559 | 0.380 |
Why?
|
| Health Care Rationing | 4 | 2001 | 83 | 0.380 |
Why?
|
| Infant | 40 | 2010 | 3046 | 0.380 |
Why?
|
| Hepatitis B Antibodies | 3 | 1999 | 15 | 0.370 |
Why?
|
| Hepacivirus | 10 | 2004 | 159 | 0.370 |
Why?
|
| Complement System Proteins | 10 | 2016 | 81 | 0.370 |
Why?
|
| T-Lymphocytes, Regulatory | 8 | 2015 | 295 | 0.370 |
Why?
|
| Lung Transplantation | 14 | 2006 | 175 | 0.360 |
Why?
|
| Recurrence | 19 | 2014 | 1139 | 0.360 |
Why?
|
| Hepatitis B virus | 4 | 2002 | 43 | 0.360 |
Why?
|
| Hepatitis | 5 | 2009 | 35 | 0.350 |
Why?
|
| Vascular Diseases | 5 | 2016 | 121 | 0.350 |
Why?
|
| Mice, Inbred Strains | 23 | 2012 | 307 | 0.350 |
Why?
|
| Aging | 6 | 2007 | 691 | 0.350 |
Why?
|
| Intestinal Mucosa | 9 | 2018 | 797 | 0.350 |
Why?
|
| Arteriovenous Fistula | 1 | 2010 | 52 | 0.350 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 99 | 0.350 |
Why?
|
| Chimera | 12 | 1997 | 56 | 0.350 |
Why?
|
| Liver Failure, Acute | 4 | 2003 | 38 | 0.340 |
Why?
|
| Pregnancy Complications | 3 | 2004 | 336 | 0.340 |
Why?
|
| Glomerular Filtration Rate | 5 | 2017 | 384 | 0.340 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2010 | 162 | 0.340 |
Why?
|
| Health Status Indicators | 1 | 2009 | 105 | 0.340 |
Why?
|
| Interleukin-12 | 7 | 2009 | 108 | 0.330 |
Why?
|
| Bone Marrow Cells | 16 | 2014 | 253 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 8 | 2016 | 509 | 0.330 |
Why?
|
| Stomach | 4 | 2015 | 108 | 0.330 |
Why?
|
| Viscera | 7 | 2004 | 17 | 0.330 |
Why?
|
| Hepatitis B Core Antigens | 4 | 2003 | 9 | 0.330 |
Why?
|
| HIV-1 | 1 | 2009 | 163 | 0.330 |
Why?
|
| Perfusion | 4 | 2018 | 203 | 0.330 |
Why?
|
| Surgical Instruments | 2 | 2019 | 57 | 0.330 |
Why?
|
| Hemophilia A | 2 | 2017 | 8 | 0.330 |
Why?
|
| Age Factors | 18 | 2015 | 1851 | 0.330 |
Why?
|
| Cyclosporins | 13 | 1991 | 59 | 0.320 |
Why?
|
| Indocyanine Green | 1 | 2008 | 22 | 0.320 |
Why?
|
| C-Peptide | 9 | 2019 | 174 | 0.320 |
Why?
|
| Coloring Agents | 1 | 2008 | 64 | 0.320 |
Why?
|
| Pancreatitis, Chronic | 2 | 2019 | 49 | 0.310 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2018 | 196 | 0.310 |
Why?
|
| Fasting | 2 | 2018 | 161 | 0.310 |
Why?
|
| Cholangiography | 2 | 2004 | 41 | 0.310 |
Why?
|
| Spleen | 25 | 2016 | 430 | 0.310 |
Why?
|
| Creatinine | 17 | 2021 | 338 | 0.310 |
Why?
|
| Steroids | 6 | 2001 | 177 | 0.310 |
Why?
|
| Editorial Policies | 1 | 2008 | 32 | 0.310 |
Why?
|
| Interleukin-10 | 11 | 1999 | 149 | 0.310 |
Why?
|
| Conflict of Interest | 1 | 2008 | 67 | 0.310 |
Why?
|
| Severity of Illness Index | 11 | 2011 | 1801 | 0.300 |
Why?
|
| Disease-Free Survival | 11 | 2018 | 1204 | 0.300 |
Why?
|
| Mouth, Edentulous | 1 | 2007 | 1 | 0.300 |
Why?
|
| Tooth Diseases | 1 | 2007 | 3 | 0.300 |
Why?
|
| Xerostomia | 1 | 2007 | 10 | 0.300 |
Why?
|
| Robotics | 1 | 2010 | 267 | 0.300 |
Why?
|
| Renal Insufficiency | 2 | 2005 | 114 | 0.300 |
Why?
|
| Lamivudine | 4 | 2002 | 13 | 0.290 |
Why?
|
| Autoimmune Diseases | 6 | 2015 | 241 | 0.290 |
Why?
|
| Transplants | 2 | 2004 | 40 | 0.290 |
Why?
|
| Acute Disease | 18 | 2006 | 826 | 0.290 |
Why?
|
| Neoplasm Staging | 10 | 2016 | 1939 | 0.290 |
Why?
|
| Autoantibodies | 6 | 2016 | 267 | 0.290 |
Why?
|
| Immunologic Factors | 3 | 2015 | 170 | 0.290 |
Why?
|
| Brain Death | 5 | 2015 | 69 | 0.290 |
Why?
|
| Retroviridae Infections | 2 | 2004 | 48 | 0.290 |
Why?
|
| Ribavirin | 3 | 2009 | 57 | 0.290 |
Why?
|
| Endogenous Retroviruses | 2 | 2003 | 10 | 0.290 |
Why?
|
| Cholangiocarcinoma | 4 | 2017 | 66 | 0.290 |
Why?
|
| Immunoglobulins | 6 | 2005 | 148 | 0.290 |
Why?
|
| Parenteral Nutrition, Total | 8 | 2017 | 41 | 0.290 |
Why?
|
| Biliary Tract | 2 | 2003 | 13 | 0.280 |
Why?
|
| Flow Cytometry | 19 | 2013 | 679 | 0.280 |
Why?
|
| Complement Activation | 7 | 2016 | 81 | 0.280 |
Why?
|
| Blood Loss, Surgical | 7 | 2018 | 112 | 0.280 |
Why?
|
| NF-kappa B | 10 | 2006 | 444 | 0.280 |
Why?
|
| Raffinose | 3 | 2004 | 24 | 0.280 |
Why?
|
| Cardiac Output | 3 | 2011 | 156 | 0.280 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2006 | 107 | 0.280 |
Why?
|
| Drug Interactions | 9 | 2004 | 248 | 0.280 |
Why?
|
| Surgical Wound Infection | 4 | 2019 | 184 | 0.280 |
Why?
|
| Leukocyte Common Antigens | 5 | 2006 | 46 | 0.270 |
Why?
|
| Transplant Recipients | 2 | 2018 | 122 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2018 | 1313 | 0.270 |
Why?
|
| Chronic Disease | 23 | 2006 | 971 | 0.270 |
Why?
|
| Glutathione | 3 | 2004 | 104 | 0.270 |
Why?
|
| Allopurinol | 3 | 2004 | 80 | 0.270 |
Why?
|
| Catheter Ablation | 3 | 2013 | 233 | 0.270 |
Why?
|
| Immunophenotyping | 16 | 2013 | 211 | 0.260 |
Why?
|
| Bile | 8 | 2018 | 57 | 0.260 |
Why?
|
| Liver, Artificial | 2 | 2002 | 7 | 0.260 |
Why?
|
| Intraoperative Complications | 2 | 2012 | 185 | 0.260 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 14 | 2009 | 112 | 0.260 |
Why?
|
| Duodenum | 2 | 2005 | 100 | 0.260 |
Why?
|
| Postoperative Period | 12 | 2016 | 303 | 0.260 |
Why?
|
| Fatty Liver | 3 | 2018 | 125 | 0.260 |
Why?
|
| Hepatitis B, Chronic | 3 | 2007 | 32 | 0.260 |
Why?
|
| Cystic Duct | 1 | 2004 | 5 | 0.260 |
Why?
|
| Ultrasonography | 3 | 2011 | 695 | 0.260 |
Why?
|
| Cytotoxicity, Immunologic | 19 | 2016 | 213 | 0.260 |
Why?
|
| Procaine | 1 | 2004 | 11 | 0.260 |
Why?
|
| Glucocorticoids | 4 | 2003 | 352 | 0.260 |
Why?
|
| Hepatitis B Surface Antigens | 7 | 2005 | 24 | 0.260 |
Why?
|
| Coinfection | 3 | 2017 | 58 | 0.260 |
Why?
|
| Colitis, Ulcerative | 1 | 2012 | 711 | 0.260 |
Why?
|
| Potassium Chloride | 1 | 2004 | 87 | 0.260 |
Why?
|
| Mannitol | 1 | 2004 | 49 | 0.250 |
Why?
|
| Diabetes Mellitus, Experimental | 7 | 2010 | 190 | 0.250 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2020 | 19 | 0.250 |
Why?
|
| Immunity, Cellular | 9 | 2010 | 177 | 0.250 |
Why?
|
| North America | 3 | 2018 | 180 | 0.250 |
Why?
|
| Gammaretrovirus | 1 | 2004 | 4 | 0.250 |
Why?
|
| Hypertension, Portal | 7 | 2015 | 47 | 0.250 |
Why?
|
| Organ Size | 7 | 2016 | 364 | 0.250 |
Why?
|
| Neoplasms | 7 | 2008 | 2898 | 0.250 |
Why?
|
| Signal Transduction | 12 | 2015 | 3241 | 0.250 |
Why?
|
| Antibody Formation | 13 | 2005 | 171 | 0.240 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2014 | 86 | 0.240 |
Why?
|
| Sodium | 3 | 2008 | 341 | 0.240 |
Why?
|
| Iliac Vein | 2 | 2001 | 30 | 0.240 |
Why?
|
| RNA, Messenger | 17 | 2013 | 1981 | 0.240 |
Why?
|
| Biopsy, Needle | 7 | 2018 | 235 | 0.240 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2003 | 11 | 0.240 |
Why?
|
| Multiple Organ Failure | 3 | 2019 | 53 | 0.240 |
Why?
|
| Vena Cava, Superior | 2 | 2010 | 59 | 0.240 |
Why?
|
| Ischemic Preconditioning | 2 | 2001 | 37 | 0.240 |
Why?
|
| Interleukins | 3 | 2016 | 134 | 0.240 |
Why?
|
| Peptides | 5 | 2017 | 639 | 0.240 |
Why?
|
| Uveitis | 2 | 2015 | 29 | 0.240 |
Why?
|
| Postoperative Care | 5 | 2011 | 221 | 0.240 |
Why?
|
| Chi-Square Distribution | 7 | 2015 | 364 | 0.240 |
Why?
|
| Ritonavir | 1 | 2003 | 12 | 0.230 |
Why?
|
| Transplantation Conditioning | 5 | 2005 | 373 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2016 | 1961 | 0.230 |
Why?
|
| Mice, Knockout | 12 | 2016 | 1924 | 0.230 |
Why?
|
| Pyrimidinones | 1 | 2003 | 36 | 0.230 |
Why?
|
| Ultrasonography, Doppler | 3 | 2016 | 80 | 0.230 |
Why?
|
| Azathioprine | 15 | 2001 | 125 | 0.230 |
Why?
|
| Teratoma | 1 | 2003 | 50 | 0.230 |
Why?
|
| Glucose | 3 | 2010 | 638 | 0.230 |
Why?
|
| Heart Failure | 3 | 2019 | 1204 | 0.230 |
Why?
|
| Blood Transfusion | 9 | 2017 | 157 | 0.230 |
Why?
|
| Proportional Hazards Models | 12 | 2017 | 859 | 0.230 |
Why?
|
| Membrane Proteins | 8 | 2015 | 1196 | 0.230 |
Why?
|
| CD40 Antigens | 7 | 2013 | 43 | 0.220 |
Why?
|
| Pyridoxal Phosphate | 1 | 2002 | 13 | 0.220 |
Why?
|
| Pyruvic Acid | 2 | 1999 | 12 | 0.220 |
Why?
|
| Nelfinavir | 1 | 2002 | 5 | 0.220 |
Why?
|
| Length of Stay | 8 | 2018 | 702 | 0.220 |
Why?
|
| Safety | 2 | 2003 | 152 | 0.220 |
Why?
|
| Edetic Acid | 1 | 2002 | 43 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2016 | 272 | 0.220 |
Why?
|
| Hemolysis | 1 | 2002 | 61 | 0.220 |
Why?
|
| Computer Systems | 1 | 2002 | 79 | 0.220 |
Why?
|
| Pathology | 1 | 2002 | 30 | 0.220 |
Why?
|
| Anti-HIV Agents | 2 | 2002 | 149 | 0.220 |
Why?
|
| Preoperative Care | 6 | 2013 | 397 | 0.220 |
Why?
|
| Testicular Neoplasms | 1 | 2003 | 105 | 0.220 |
Why?
|
| Heart Arrest | 3 | 2000 | 265 | 0.210 |
Why?
|
| Bioreactors | 1 | 2002 | 10 | 0.210 |
Why?
|
| Young Adult | 11 | 2019 | 5976 | 0.210 |
Why?
|
| Bile Duct Neoplasms | 4 | 2017 | 79 | 0.210 |
Why?
|
| Adenoviridae | 6 | 2005 | 345 | 0.210 |
Why?
|
| Drug Administration Schedule | 15 | 2015 | 916 | 0.210 |
Why?
|
| Allografts | 4 | 2016 | 172 | 0.210 |
Why?
|
| Bilirubin | 10 | 2023 | 125 | 0.210 |
Why?
|
| CD28 Antigens | 6 | 2003 | 88 | 0.210 |
Why?
|
| Leishmania | 1 | 2021 | 7 | 0.210 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2021 | 5 | 0.210 |
Why?
|
| Macrophages, Peritoneal | 1 | 2021 | 21 | 0.210 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2021 | 8 | 0.200 |
Why?
|
| Antiprotozoal Agents | 1 | 2021 | 33 | 0.200 |
Why?
|
| Hypernatremia | 2 | 2008 | 9 | 0.200 |
Why?
|
| Prednisolone | 1 | 2001 | 41 | 0.200 |
Why?
|
| Interferon-alpha | 6 | 2009 | 233 | 0.200 |
Why?
|
| HIV Seropositivity | 3 | 2006 | 49 | 0.200 |
Why?
|
| Rats, Inbred ACI | 15 | 2000 | 25 | 0.200 |
Why?
|
| Smoking | 1 | 2005 | 609 | 0.200 |
Why?
|
| Prodrugs | 1 | 2001 | 46 | 0.200 |
Why?
|
| Graft Enhancement, Immunologic | 5 | 2005 | 13 | 0.200 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2002 | 33 | 0.190 |
Why?
|
| Major Histocompatibility Complex | 9 | 1999 | 81 | 0.190 |
Why?
|
| Hemodynamics | 5 | 2018 | 710 | 0.190 |
Why?
|
| Analysis of Variance | 13 | 2012 | 912 | 0.190 |
Why?
|
| Liver Function Tests | 12 | 2005 | 93 | 0.190 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2002 | 229 | 0.190 |
Why?
|
| Case-Control Studies | 10 | 2016 | 1805 | 0.190 |
Why?
|
| Cell Differentiation | 9 | 2018 | 1458 | 0.190 |
Why?
|
| Blood Proteins | 5 | 2004 | 144 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2018 | 814 | 0.190 |
Why?
|
| Herpes Simplex | 1 | 2002 | 202 | 0.190 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 246 | 0.190 |
Why?
|
| Histocompatibility Antigens | 3 | 2001 | 35 | 0.190 |
Why?
|
| Operative Time | 5 | 2019 | 127 | 0.190 |
Why?
|
| Kidney Function Tests | 7 | 2015 | 123 | 0.190 |
Why?
|
| Probability | 7 | 2006 | 355 | 0.190 |
Why?
|
| Treatment Failure | 8 | 2002 | 285 | 0.190 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2000 | 5 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 6 | 2005 | 50 | 0.180 |
Why?
|
| Donor Selection | 4 | 2018 | 67 | 0.180 |
Why?
|
| CD40 Ligand | 11 | 2006 | 69 | 0.180 |
Why?
|
| Regional Blood Flow | 3 | 2016 | 197 | 0.180 |
Why?
|
| Actuarial Analysis | 17 | 1999 | 66 | 0.180 |
Why?
|
| Disease Progression | 6 | 2017 | 1531 | 0.180 |
Why?
|
| Leukocytes | 6 | 2003 | 202 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 237 | 0.180 |
Why?
|
| Interleukin-6 | 6 | 2000 | 256 | 0.180 |
Why?
|
| Antibodies | 8 | 2001 | 350 | 0.180 |
Why?
|
| Complement Factor H | 2 | 2016 | 34 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 2016 | 95 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.170 |
Why?
|
| Transplantation, Autologous | 7 | 2019 | 331 | 0.170 |
Why?
|
| Renal Plasma Flow, Effective | 1 | 1999 | 1 | 0.170 |
Why?
|
| Iodohippuric Acid | 1 | 1999 | 2 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 8 | 2007 | 301 | 0.170 |
Why?
|
| Algorithms | 3 | 2016 | 1830 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2005 | 263 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 13 | 2017 | 927 | 0.170 |
Why?
|
| Receptor, Anaphylatoxin C5a | 2 | 2016 | 21 | 0.170 |
Why?
|
| Killer Cells, Natural | 8 | 2009 | 267 | 0.170 |
Why?
|
| Oligodeoxyribonucleotides | 7 | 2006 | 126 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2013 | 272 | 0.170 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2016 | 53 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2018 | 1578 | 0.170 |
Why?
|
| Angina Pectoris | 1 | 2018 | 28 | 0.170 |
Why?
|
| Resource Allocation | 2 | 1996 | 65 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2013 | 2601 | 0.170 |
Why?
|
| Interleukin-4 | 11 | 2002 | 127 | 0.170 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 2232 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 180 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 639 | 0.170 |
Why?
|
| Transplantation, Isogeneic | 10 | 1999 | 39 | 0.170 |
Why?
|
| Hepatic Encephalopathy | 2 | 1996 | 40 | 0.170 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 3 | 2003 | 16 | 0.170 |
Why?
|
| Aorta | 5 | 2001 | 280 | 0.160 |
Why?
|
| Mesocricetus | 16 | 2001 | 107 | 0.160 |
Why?
|
| Comorbidity | 2 | 2017 | 943 | 0.160 |
Why?
|
| Genotype | 8 | 2016 | 1851 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 78 | 0.160 |
Why?
|
| Quality of Life | 5 | 2017 | 1585 | 0.160 |
Why?
|
| Sarcoma | 4 | 2010 | 215 | 0.160 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1999 | 66 | 0.160 |
Why?
|
| Adiponectin | 1 | 2018 | 24 | 0.160 |
Why?
|
| Wounds, Gunshot | 2 | 2010 | 71 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 2 | 2017 | 105 | 0.160 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 19 | 0.160 |
Why?
|
| Lymphoid Tissue | 7 | 2001 | 57 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 8 | 2001 | 144 | 0.160 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 19 | 0.160 |
Why?
|
| Recovery of Function | 2 | 2010 | 272 | 0.160 |
Why?
|
| Complement C3 | 3 | 2013 | 58 | 0.160 |
Why?
|
| Models, Biological | 3 | 2009 | 1749 | 0.160 |
Why?
|
| Histocompatibility | 4 | 1996 | 71 | 0.160 |
Why?
|
| Receptors, Complement | 2 | 2015 | 46 | 0.160 |
Why?
|
| Receptors, Interferon | 2 | 2015 | 31 | 0.160 |
Why?
|
| Syndrome | 5 | 2023 | 446 | 0.160 |
Why?
|
| Pennsylvania | 12 | 2002 | 75 | 0.160 |
Why?
|
| Prevalence | 3 | 2007 | 1239 | 0.150 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 40 | 0.150 |
Why?
|
| Receptors, CCR2 | 1 | 2017 | 35 | 0.150 |
Why?
|
| Leukocyte Transfusion | 6 | 2004 | 15 | 0.150 |
Why?
|
| Iowa | 1 | 2017 | 35 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.150 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1997 | 27 | 0.150 |
Why?
|
| Neutrophils | 2 | 2016 | 307 | 0.150 |
Why?
|
| Conversion to Open Surgery | 1 | 2017 | 11 | 0.150 |
Why?
|
| Ascites | 2 | 2011 | 55 | 0.150 |
Why?
|
| Extracorporeal Circulation | 1 | 1997 | 26 | 0.150 |
Why?
|
| Cell Division | 13 | 2007 | 696 | 0.150 |
Why?
|
| Lipopolysaccharides | 4 | 2009 | 286 | 0.150 |
Why?
|
| Genetic Vectors | 7 | 2005 | 439 | 0.150 |
Why?
|
| Alemtuzumab | 6 | 2006 | 83 | 0.150 |
Why?
|
| Fetal Death | 1 | 1997 | 56 | 0.150 |
Why?
|
| Body Mass Index | 4 | 2016 | 770 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 7 | 2010 | 167 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 116 | 0.150 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1996 | 18 | 0.150 |
Why?
|
| Human Growth Hormone | 1 | 2017 | 54 | 0.150 |
Why?
|
| Necrosis | 7 | 2014 | 204 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 196 | 0.140 |
Why?
|
| Isoantigens | 5 | 2011 | 66 | 0.140 |
Why?
|
| Macrophages | 7 | 2001 | 554 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 104 | 0.140 |
Why?
|
| Transfection | 7 | 2006 | 896 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 100 | 0.140 |
Why?
|
| Oxygen Consumption | 2 | 2014 | 239 | 0.140 |
Why?
|
| Lymphocyte Depletion | 3 | 1995 | 97 | 0.140 |
Why?
|
| Vascular Closure Devices | 1 | 2016 | 3 | 0.140 |
Why?
|
| Pericytes | 1 | 2016 | 12 | 0.140 |
Why?
|
| Cell Movement | 8 | 2002 | 758 | 0.140 |
Why?
|
| Ethics, Medical | 3 | 2008 | 306 | 0.140 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 999 | 0.140 |
Why?
|
| Dissection | 1 | 2016 | 42 | 0.140 |
Why?
|
| Obesity, Morbid | 2 | 2015 | 225 | 0.140 |
Why?
|
| Postpartum Period | 1 | 1997 | 135 | 0.140 |
Why?
|
| Catecholamines | 2 | 2010 | 88 | 0.140 |
Why?
|
| Regression Analysis | 6 | 2010 | 596 | 0.140 |
Why?
|
| Aorta, Thoracic | 3 | 2003 | 165 | 0.130 |
Why?
|
| Online Systems | 1 | 2015 | 24 | 0.130 |
Why?
|
| Growth Substances | 3 | 2007 | 80 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 120 | 0.130 |
Why?
|
| Portasystemic Shunt, Surgical | 2 | 2008 | 12 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 240 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 9 | 2004 | 73 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 1056 | 0.130 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1995 | 18 | 0.130 |
Why?
|
| Heart Atria | 1 | 1997 | 250 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 84 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 87 | 0.130 |
Why?
|
| Mesoderm | 1 | 2015 | 108 | 0.130 |
Why?
|
| China | 3 | 2014 | 228 | 0.130 |
Why?
|
| Insulin-Secreting Cells | 1 | 2018 | 397 | 0.130 |
Why?
|
| Bone Marrow | 7 | 1996 | 435 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 87 | 0.130 |
Why?
|
| Angioplasty, Balloon | 1 | 1995 | 95 | 0.130 |
Why?
|
| Epithelium | 3 | 2014 | 319 | 0.130 |
Why?
|
| Diabetes Mellitus | 7 | 2001 | 806 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Autoimmunity | 2 | 2012 | 160 | 0.130 |
Why?
|
| Herpesviridae Infections | 3 | 2000 | 46 | 0.130 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 228 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2014 | 4 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 170 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 378 | 0.130 |
Why?
|
| CTLA-4 Antigen | 11 | 2003 | 135 | 0.130 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2000 | 31 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2002 | 162 | 0.130 |
Why?
|
| Amphotericin B | 3 | 2003 | 34 | 0.120 |
Why?
|
| Government | 1 | 2014 | 9 | 0.120 |
Why?
|
| Arginase | 1 | 2014 | 16 | 0.120 |
Why?
|
| Age Distribution | 6 | 2006 | 204 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2012 | 6509 | 0.120 |
Why?
|
| Blood Flow Velocity | 3 | 2011 | 197 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2016 | 549 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.120 |
Why?
|
| Sarcopenia | 1 | 2014 | 13 | 0.120 |
Why?
|
| ABO Blood-Group System | 4 | 1997 | 62 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1995 | 127 | 0.120 |
Why?
|
| Social Values | 1 | 2014 | 44 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 418 | 0.120 |
Why?
|
| Immunization | 6 | 2005 | 158 | 0.120 |
Why?
|
| Laparotomy | 2 | 2016 | 59 | 0.120 |
Why?
|
| Retina | 1 | 2016 | 213 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 819 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 350 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2013 | 10 | 0.120 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2013 | 4 | 0.120 |
Why?
|
| Killer Cells, Lymphokine-Activated | 3 | 1998 | 27 | 0.120 |
Why?
|
| Hypertension | 6 | 2003 | 1141 | 0.120 |
Why?
|
| Pulmonary Alveoli | 4 | 1987 | 71 | 0.120 |
Why?
|
| RNA, Viral | 4 | 2004 | 327 | 0.120 |
Why?
|
| Heart-Lung Transplantation | 5 | 1991 | 17 | 0.120 |
Why?
|
| Tretinoin | 1 | 2014 | 126 | 0.120 |
Why?
|
| Birth Weight | 2 | 2004 | 145 | 0.120 |
Why?
|
| Hospitals, University | 2 | 2012 | 194 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2016 | 377 | 0.120 |
Why?
|
| Abatacept | 10 | 2002 | 83 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2015 | 225 | 0.120 |
Why?
|
| Cell Line | 7 | 2018 | 2468 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 220 | 0.110 |
Why?
|
| Regeneration | 1 | 2014 | 143 | 0.110 |
Why?
|
| Bacterial Infections | 2 | 2009 | 182 | 0.110 |
Why?
|
| Consensus | 3 | 2023 | 335 | 0.110 |
Why?
|
| Sex Characteristics | 4 | 2006 | 319 | 0.110 |
Why?
|
| Homeostasis | 3 | 2016 | 409 | 0.110 |
Why?
|
| Phenotype | 11 | 2018 | 2378 | 0.110 |
Why?
|
| Infant, Newborn | 6 | 2010 | 2379 | 0.110 |
Why?
|
| Cryptococcosis | 2 | 2003 | 11 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 325 | 0.110 |
Why?
|
| Hepatitis, Viral, Human | 5 | 1997 | 25 | 0.110 |
Why?
|
| Area Under Curve | 4 | 2017 | 334 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 60 | 0.110 |
Why?
|
| Brain Diseases | 3 | 2000 | 180 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2014 | 179 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 194 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 407 | 0.110 |
Why?
|
| Bronchi | 4 | 1987 | 229 | 0.110 |
Why?
|
| General Surgery | 1 | 2015 | 229 | 0.110 |
Why?
|
| Attitude to Health | 2 | 2005 | 220 | 0.110 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2012 | 37 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2006 | 930 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2013 | 36 | 0.110 |
Why?
|
| Clone Cells | 3 | 2003 | 213 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1995 | 332 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 8 | 2013 | 303 | 0.110 |
Why?
|
| Viral Load | 3 | 2012 | 148 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2012 | 12 | 0.110 |
Why?
|
| Administration, Oral | 11 | 2001 | 684 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3362 | 0.110 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2010 | 19 | 0.110 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2011 | 3 | 0.110 |
Why?
|
| Thymus Gland | 3 | 1995 | 195 | 0.100 |
Why?
|
| Pregnancy | 5 | 2004 | 2894 | 0.100 |
Why?
|
| Antigens, Heterophile | 4 | 2002 | 6 | 0.100 |
Why?
|
| Morbidity | 2 | 2011 | 148 | 0.100 |
Why?
|
| Adenosine Triphosphate | 2 | 2010 | 314 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 879 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.100 |
Why?
|
| Models, Animal | 7 | 2009 | 263 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2013 | 71 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2011 | 55 | 0.100 |
Why?
|
| Virus Diseases | 1 | 1992 | 97 | 0.100 |
Why?
|
| Splenic Artery | 1 | 2011 | 11 | 0.100 |
Why?
|
| Nervous System Diseases | 3 | 2003 | 151 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 1994 | 262 | 0.100 |
Why?
|
| Methylprednisolone | 4 | 2004 | 66 | 0.100 |
Why?
|
| Purines | 1 | 2011 | 91 | 0.100 |
Why?
|
| Acanthocytes | 1 | 2011 | 3 | 0.100 |
Why?
|
| Galactosyltransferases | 2 | 2001 | 40 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2011 | 20 | 0.100 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 113 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2016 | 839 | 0.100 |
Why?
|
| Anemia, Hemolytic | 1 | 2011 | 19 | 0.100 |
Why?
|
| Th1 Cells | 3 | 2015 | 164 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 2 | 2009 | 166 | 0.100 |
Why?
|
| Antigen Presentation | 5 | 2007 | 209 | 0.100 |
Why?
|
| Antigens, Surface | 4 | 2016 | 101 | 0.100 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2010 | 5 | 0.100 |
Why?
|
| Liver Cirrhosis, Alcoholic | 4 | 2001 | 23 | 0.100 |
Why?
|
| Thymectomy | 1 | 1990 | 31 | 0.100 |
Why?
|
| Curriculum | 1 | 2015 | 539 | 0.100 |
Why?
|
| Electrocoagulation | 1 | 2010 | 22 | 0.100 |
Why?
|
| Diabetic Nephropathies | 7 | 1999 | 248 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 1991 | 0.090 |
Why?
|
| Biphenyl Compounds | 4 | 1994 | 68 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2006 | 267 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2011 | 153 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 26 | 0.090 |
Why?
|
| Physiology | 1 | 2010 | 16 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2004 | 429 | 0.090 |
Why?
|
| Hyperlipidemias | 2 | 2001 | 95 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 25 | 0.090 |
Why?
|
| Sex Distribution | 3 | 2006 | 173 | 0.090 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2000 | 48 | 0.090 |
Why?
|
| Lymphangiectasis, Intestinal | 1 | 2009 | 2 | 0.090 |
Why?
|
| Alanine Transaminase | 7 | 2000 | 73 | 0.090 |
Why?
|
| Clinical Protocols | 2 | 2010 | 156 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 4 | 2013 | 139 | 0.090 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2009 | 6 | 0.090 |
Why?
|
| Receptors, KIR2DL2 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Bacterial Translocation | 2 | 2000 | 26 | 0.090 |
Why?
|
| Buffers | 1 | 2009 | 26 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2903 | 0.090 |
Why?
|
| Receptors, KIR | 1 | 2009 | 10 | 0.090 |
Why?
|
| Nitric Oxide | 3 | 2021 | 278 | 0.090 |
Why?
|
| Multiple Trauma | 1 | 2010 | 34 | 0.090 |
Why?
|
| Equipment Design | 3 | 2018 | 406 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2012 | 70 | 0.090 |
Why?
|
| Alprostadil | 3 | 1995 | 25 | 0.090 |
Why?
|
| Cytidine | 3 | 1994 | 17 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2009 | 51 | 0.090 |
Why?
|
| Blood Pressure | 4 | 2011 | 1143 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2357 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 318 | 0.090 |
Why?
|
| Cell Culture Techniques | 3 | 2007 | 188 | 0.090 |
Why?
|
| Vasoconstriction | 1 | 2009 | 93 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 1565 | 0.090 |
Why?
|
| Endotoxins | 1 | 2009 | 36 | 0.090 |
Why?
|
| Molecular Sequence Data | 7 | 2003 | 3030 | 0.090 |
Why?
|
| ROC Curve | 3 | 2017 | 752 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 300 | 0.090 |
Why?
|
| Monitoring, Immunologic | 2 | 2006 | 17 | 0.090 |
Why?
|
| Epitopes | 5 | 2004 | 255 | 0.090 |
Why?
|
| Transplantation, Heterotopic | 6 | 1994 | 45 | 0.090 |
Why?
|
| DNA | 6 | 2005 | 1294 | 0.090 |
Why?
|
| Obesity | 1 | 2016 | 963 | 0.090 |
Why?
|
| Biomarkers | 7 | 2018 | 1718 | 0.090 |
Why?
|
| Graft vs Host Reaction | 4 | 1997 | 15 | 0.090 |
Why?
|
| Patient Participation | 1 | 2011 | 216 | 0.090 |
Why?
|
| Body Image | 1 | 2009 | 76 | 0.090 |
Why?
|
| Immunohistochemistry | 8 | 2007 | 1753 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 375 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2003 | 557 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 36 | 0.080 |
Why?
|
| Pancreatitis | 2 | 2003 | 87 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 2009 | 80 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2008 | 83 | 0.080 |
Why?
|
| Abdominal Neoplasms | 3 | 1995 | 39 | 0.080 |
Why?
|
| Travel | 1 | 2009 | 68 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 81 | 0.080 |
Why?
|
| Models, Anatomic | 1 | 2009 | 91 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2001 | 865 | 0.080 |
Why?
|
| Informed Consent | 3 | 2014 | 266 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 238 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2015 | 1540 | 0.080 |
Why?
|
| Lectins, C-Type | 3 | 2006 | 85 | 0.080 |
Why?
|
| Isoxazoles | 2 | 1999 | 77 | 0.080 |
Why?
|
| Cholesterol | 5 | 2018 | 356 | 0.080 |
Why?
|
| Influenza, Human | 2 | 2002 | 329 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 1208 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 552 | 0.080 |
Why?
|
| Turner Syndrome | 1 | 2008 | 27 | 0.080 |
Why?
|
| Pentoxifylline | 2 | 1999 | 9 | 0.080 |
Why?
|
| Blood Coagulation | 2 | 2002 | 91 | 0.080 |
Why?
|
| Recombinant Proteins | 8 | 2009 | 1014 | 0.080 |
Why?
|
| Radiation Chimera | 3 | 1997 | 23 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 480 | 0.080 |
Why?
|
| Glucuronates | 3 | 2005 | 22 | 0.080 |
Why?
|
| Risk | 2 | 2020 | 674 | 0.080 |
Why?
|
| Glucuronides | 3 | 2005 | 34 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2002 | 265 | 0.080 |
Why?
|
| Reference Values | 3 | 2005 | 674 | 0.080 |
Why?
|
| HLA-DR Antigens | 7 | 2018 | 61 | 0.080 |
Why?
|
| Mesenteric Veins | 3 | 1996 | 34 | 0.080 |
Why?
|
| Host vs Graft Reaction | 2 | 1997 | 3 | 0.080 |
Why?
|
| Cell Transplantation | 4 | 2010 | 47 | 0.080 |
Why?
|
| Base Sequence | 5 | 2003 | 2330 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2005 | 170 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 109 | 0.070 |
Why?
|
| Creatine | 2 | 2005 | 23 | 0.070 |
Why?
|
| Receptors, Cell Surface | 3 | 2006 | 286 | 0.070 |
Why?
|
| Virus Replication | 2 | 2001 | 319 | 0.070 |
Why?
|
| Glucose Tolerance Test | 3 | 2018 | 228 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2009 | 280 | 0.070 |
Why?
|
| Longitudinal Studies | 5 | 2003 | 1019 | 0.070 |
Why?
|
| Portal System | 1 | 2006 | 13 | 0.070 |
Why?
|
| Papio | 4 | 1997 | 82 | 0.070 |
Why?
|
| Intraoperative Period | 2 | 2004 | 90 | 0.070 |
Why?
|
| Tunica Intima | 3 | 2001 | 59 | 0.070 |
Why?
|
| Drug Approval | 2 | 1998 | 62 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1464 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2003 | 173 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 9 | 0.070 |
Why?
|
| Caroli Disease | 1 | 2006 | 1 | 0.070 |
Why?
|
| Inflammation | 5 | 2021 | 920 | 0.070 |
Why?
|
| Hypertonic Solutions | 1 | 2006 | 17 | 0.070 |
Why?
|
| Tumor Virus Infections | 2 | 1999 | 81 | 0.070 |
Why?
|
| Interleukin-3 | 1 | 2006 | 36 | 0.070 |
Why?
|
| Stem Cells | 2 | 2000 | 351 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2015 | 376 | 0.070 |
Why?
|
| Clonal Deletion | 3 | 2005 | 23 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2015 | 1004 | 0.070 |
Why?
|
| Liver Regeneration | 3 | 2004 | 32 | 0.070 |
Why?
|
| HIV Seronegativity | 1 | 2005 | 12 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2005 | 78 | 0.070 |
Why?
|
| Psoriasis | 4 | 1992 | 240 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2003 | 117 | 0.070 |
Why?
|
| Warm Ischemia | 2 | 2016 | 28 | 0.070 |
Why?
|
| Up-Regulation | 4 | 2015 | 712 | 0.070 |
Why?
|
| Hemangioma, Cavernous | 1 | 2006 | 69 | 0.070 |
Why?
|
| Rituximab | 1 | 2005 | 116 | 0.070 |
Why?
|
| Infusions, Intravenous | 4 | 2016 | 429 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 79 | 0.060 |
Why?
|
| Reproducibility of Results | 6 | 2011 | 2705 | 0.060 |
Why?
|
| Lymphocyte Transfusion | 3 | 1997 | 41 | 0.060 |
Why?
|
| Intestinal Absorption | 4 | 1996 | 124 | 0.060 |
Why?
|
| Acyclovir | 3 | 2002 | 107 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2017 | 297 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 33 | 0.060 |
Why?
|
| Logistic Models | 3 | 2018 | 1186 | 0.060 |
Why?
|
| Melanoma, Experimental | 1 | 2005 | 103 | 0.060 |
Why?
|
| Opportunistic Infections | 2 | 1995 | 59 | 0.060 |
Why?
|
| Concanavalin A | 3 | 2000 | 52 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2003 | 118 | 0.060 |
Why?
|
| Whole-Body Irradiation | 6 | 2000 | 63 | 0.060 |
Why?
|
| Myocardium | 5 | 1997 | 529 | 0.060 |
Why?
|
| Antibodies, Viral | 3 | 2000 | 293 | 0.060 |
Why?
|
| Cyclophosphamide | 4 | 1998 | 299 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2005 | 148 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2005 | 152 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 74 | 0.060 |
Why?
|
| Terminal Repeat Sequences | 1 | 2003 | 9 | 0.060 |
Why?
|
| Fludrocortisone | 1 | 2003 | 3 | 0.060 |
Why?
|
| Autopsy | 5 | 2001 | 116 | 0.060 |
Why?
|
| Thermolysin | 1 | 2003 | 9 | 0.060 |
Why?
|
| Lopinavir | 1 | 2003 | 5 | 0.060 |
Why?
|
| Polyenes | 3 | 1992 | 8 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2007 | 428 | 0.060 |
Why?
|
| Tissue Preservation | 1 | 2003 | 14 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2019 | 572 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2005 | 234 | 0.060 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2003 | 33 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2004 | 252 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2002 | 71 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2003 | 68 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 156 | 0.060 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2004 | 52 | 0.060 |
Why?
|
| Epithelial Cells | 5 | 2001 | 669 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2003 | 69 | 0.060 |
Why?
|
| Collagenases | 1 | 2003 | 39 | 0.060 |
Why?
|
| Pregnancy in Diabetics | 1 | 2003 | 37 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1197 | 0.060 |
Why?
|
| Laboratories | 1 | 2023 | 43 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2006 | 152 | 0.060 |
Why?
|
| Serum Albumin | 2 | 2001 | 130 | 0.060 |
Why?
|
| Veterans | 2 | 1996 | 72 | 0.060 |
Why?
|
| SEER Program | 1 | 2004 | 190 | 0.060 |
Why?
|
| Retreatment | 1 | 2003 | 107 | 0.060 |
Why?
|
| Phenytoin | 1 | 2003 | 16 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 94 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2003 | 41 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2003 | 342 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2003 | 79 | 0.060 |
Why?
|
| Muromonab-CD3 | 5 | 2000 | 69 | 0.060 |
Why?
|
| Scedosporium | 1 | 2002 | 1 | 0.060 |
Why?
|
| Pseudallescheria | 1 | 2002 | 2 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2003 | 104 | 0.060 |
Why?
|
| Immunoassay | 1 | 2003 | 92 | 0.060 |
Why?
|
| Registries | 3 | 2017 | 702 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2360 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 181 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2002 | 91 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 37 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 72 | 0.050 |
Why?
|
| Lactic Acid | 2 | 2018 | 90 | 0.050 |
Why?
|
| Rats, Inbred BN | 7 | 1997 | 37 | 0.050 |
Why?
|
| Reperfusion | 2 | 1999 | 31 | 0.050 |
Why?
|
| Forecasting | 2 | 2014 | 304 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 302 | 0.050 |
Why?
|
| Enteral Nutrition | 3 | 1998 | 102 | 0.050 |
Why?
|
| Azoles | 1 | 2002 | 3 | 0.050 |
Why?
|
| Telepathology | 1 | 2001 | 1 | 0.050 |
Why?
|
| Gene Expression | 6 | 2009 | 1284 | 0.050 |
Why?
|
| Enoxaparin | 1 | 2002 | 23 | 0.050 |
Why?
|
| Transportation | 1 | 2002 | 18 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2002 | 17 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2003 | 232 | 0.050 |
Why?
|
| Remote Consultation | 1 | 2001 | 16 | 0.050 |
Why?
|
| Sex Factors | 5 | 1997 | 1054 | 0.050 |
Why?
|
| Leishmaniasis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2001 | 79 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 146 | 0.050 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2001 | 15 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2000 | 220 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2001 | 315 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2002 | 69 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2002 | 46 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2001 | 39 | 0.050 |
Why?
|
| Hypotension | 1 | 2002 | 70 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 153 | 0.050 |
Why?
|
| Fungi | 1 | 2002 | 65 | 0.050 |
Why?
|
| Hemoperfusion | 1 | 2001 | 5 | 0.050 |
Why?
|
| Rats, Nude | 3 | 1997 | 22 | 0.050 |
Why?
|
| Tryptophan Oxygenase | 1 | 2001 | 8 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2001 | 15 | 0.050 |
Why?
|
| Disaccharides | 1 | 2001 | 23 | 0.050 |
Why?
|
| Half-Life | 1 | 2001 | 96 | 0.050 |
Why?
|
| Immune Complex Diseases | 1 | 2001 | 19 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2002 | 107 | 0.050 |
Why?
|
| Triglycerides | 2 | 2018 | 232 | 0.050 |
Why?
|
| Hemostatics | 1 | 2001 | 56 | 0.050 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2000 | 10 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 231 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 339 | 0.050 |
Why?
|
| Aspirin | 1 | 2002 | 156 | 0.050 |
Why?
|
| Antigens | 4 | 2003 | 228 | 0.050 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 5 | 2001 | 22 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2001 | 94 | 0.050 |
Why?
|
| Tryptophan | 1 | 2001 | 90 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1997 | 44 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2000 | 60 | 0.050 |
Why?
|
| B7-2 Antigen | 4 | 2003 | 40 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2001 | 229 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2000 | 22 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2002 | 482 | 0.050 |
Why?
|
| Imidazoles | 1 | 2021 | 162 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 391 | 0.050 |
Why?
|
| Herpesvirus 6, Human | 1 | 2000 | 19 | 0.050 |
Why?
|
| Enteritis | 2 | 1997 | 21 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 147 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 1998 | 127 | 0.050 |
Why?
|
| Body Weight | 6 | 2000 | 459 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2018 | 293 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 645 | 0.050 |
Why?
|
| Abdomen | 2 | 1991 | 122 | 0.050 |
Why?
|
| Hepatitis D | 1 | 2000 | 6 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 1995 | 435 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 148 | 0.050 |
Why?
|
| Myocarditis | 1 | 2000 | 50 | 0.050 |
Why?
|
| Platelet Count | 3 | 1998 | 92 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 66 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 58 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1999 | 23 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 399 | 0.050 |
Why?
|
| Evolution, Molecular | 2 | 2006 | 813 | 0.050 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1999 | 12 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2002 | 202 | 0.040 |
Why?
|
| Antibodies, Heterophile | 5 | 1997 | 20 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2000 | 169 | 0.040 |
Why?
|
| Free Radicals | 1 | 1999 | 73 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 2013 | 1686 | 0.040 |
Why?
|
| Cytomegalovirus | 2 | 1997 | 76 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2000 | 81 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2000 | 163 | 0.040 |
Why?
|
| Vasculitis | 3 | 1997 | 39 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1999 | 32 | 0.040 |
Why?
|
| Radioactive Tracers | 1 | 1999 | 6 | 0.040 |
Why?
|
| Stavudine | 1 | 1999 | 4 | 0.040 |
Why?
|
| Supine Position | 1 | 2019 | 30 | 0.040 |
Why?
|
| Europe | 2 | 2015 | 309 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2006 | 1823 | 0.040 |
Why?
|
| Thermodilution | 1 | 1999 | 21 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 39 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 379 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 1999 | 76 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 8 | 0.040 |
Why?
|
| Klatskin Tumor | 1 | 1998 | 1 | 0.040 |
Why?
|
| Lymph Nodes | 4 | 2004 | 533 | 0.040 |
Why?
|
| Day Care, Medical | 1 | 1998 | 11 | 0.040 |
Why?
|
| Enterococcus | 1 | 1999 | 35 | 0.040 |
Why?
|
| Cell Survival | 2 | 2016 | 969 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 73 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 269 | 0.040 |
Why?
|
| Cell Communication | 2 | 2013 | 194 | 0.040 |
Why?
|
| Common Bile Duct | 1 | 1998 | 19 | 0.040 |
Why?
|
| Life Tables | 2 | 1999 | 48 | 0.040 |
Why?
|
| Guinea Pigs | 4 | 2000 | 171 | 0.040 |
Why?
|
| Genome | 1 | 2001 | 372 | 0.040 |
Why?
|
| Hospital Units | 1 | 1998 | 30 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 1998 | 21 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2002 | 408 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2019 | 63 | 0.040 |
Why?
|
| Y Chromosome | 2 | 1995 | 28 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 134 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 1998 | 16 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 1998 | 11 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2017 | 678 | 0.040 |
Why?
|
| Chlorzoxazone | 1 | 1998 | 5 | 0.040 |
Why?
|
| Lymphoma | 3 | 1999 | 262 | 0.040 |
Why?
|
| Alopecia | 1 | 1998 | 34 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 1219 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 3 | 2006 | 305 | 0.040 |
Why?
|
| Immunity | 1 | 1999 | 136 | 0.040 |
Why?
|
| Flaviviridae | 1 | 1997 | 3 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2018 | 105 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2501 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 1995 | 510 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1995 | 159 | 0.040 |
Why?
|
| Rats, Inbred BUF | 1 | 1997 | 4 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 488 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 1997 | 16 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1998 | 27 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 683 | 0.040 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2018 | 126 | 0.040 |
Why?
|
| Vasodilation | 1 | 1997 | 96 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 429 | 0.040 |
Why?
|
| Eating | 1 | 1998 | 166 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 183 | 0.040 |
Why?
|
| Contrast Media | 1 | 2002 | 1078 | 0.040 |
Why?
|
| Peritoneovenous Shunt | 1 | 1997 | 1 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 1997 | 41 | 0.040 |
Why?
|
| Arteriosclerosis Obliterans | 1 | 1997 | 6 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1920 | 0.040 |
Why?
|
| Suture Techniques | 1 | 1998 | 135 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 30 | 0.040 |
Why?
|
| Cell Separation | 4 | 2003 | 196 | 0.040 |
Why?
|
| Endarterectomy | 1 | 1996 | 20 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 37 | 0.040 |
Why?
|
| Epidermal Growth Factor | 2 | 1994 | 119 | 0.040 |
Why?
|
| Receptors, Interleukin | 2 | 2009 | 35 | 0.040 |
Why?
|
| Hernia, Ventral | 1 | 1997 | 24 | 0.040 |
Why?
|
| Cold Ischemia | 1 | 2016 | 17 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Monocytes | 3 | 2005 | 214 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 243 | 0.040 |
Why?
|
| Neuraminic Acids | 1 | 2016 | 10 | 0.040 |
Why?
|
| Military Personnel | 1 | 1998 | 85 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2016 | 38 | 0.040 |
Why?
|
| Pain Management | 1 | 2017 | 127 | 0.040 |
Why?
|
| Immune Sera | 4 | 2001 | 52 | 0.040 |
Why?
|
| Protein Binding | 2 | 2015 | 1456 | 0.040 |
Why?
|
| Jaundice, Neonatal | 1 | 1996 | 32 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 1169 | 0.040 |
Why?
|
| Complement C4a | 1 | 2016 | 3 | 0.040 |
Why?
|
| Ficoll | 1 | 2016 | 1 | 0.040 |
Why?
|
| Prejudice | 1 | 1996 | 49 | 0.040 |
Why?
|
| CD11c Antigen | 2 | 2006 | 11 | 0.030 |
Why?
|
| Carrier Proteins | 3 | 2002 | 673 | 0.030 |
Why?
|
| Complement C3a | 1 | 2016 | 11 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 91 | 0.030 |
Why?
|
| Complement C5a | 1 | 2016 | 24 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 1997 | 88 | 0.030 |
Why?
|
| Research Report | 1 | 2016 | 44 | 0.030 |
Why?
|
| Temperature | 2 | 2004 | 396 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2013 | 782 | 0.030 |
Why?
|
| Skin | 2 | 1997 | 554 | 0.030 |
Why?
|
| Fungemia | 1 | 1996 | 15 | 0.030 |
Why?
|
| Delayed Graft Function | 1 | 2015 | 12 | 0.030 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1995 | 9 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1999 | 597 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 5 | 1995 | 34 | 0.030 |
Why?
|
| Gastrointestinal Motility | 2 | 1992 | 25 | 0.030 |
Why?
|
| Gestational Age | 1 | 1997 | 311 | 0.030 |
Why?
|
| Hepatitis B Antigens | 1 | 1995 | 2 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1997 | 306 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2012 | 292 | 0.030 |
Why?
|
| Candidiasis | 1 | 1996 | 36 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 131 | 0.030 |
Why?
|
| Chickenpox | 1 | 1995 | 39 | 0.030 |
Why?
|
| Public Policy | 1 | 1996 | 52 | 0.030 |
Why?
|
| Heparin | 1 | 2016 | 175 | 0.030 |
Why?
|
| Expert Systems | 1 | 1995 | 18 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 1995 | 43 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1995 | 45 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 76 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2015 | 24 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| H-Y Antigen | 1 | 1995 | 1 | 0.030 |
Why?
|
| Critical Care | 1 | 1998 | 370 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1997 | 292 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2015 | 168 | 0.030 |
Why?
|
| Dogs | 3 | 1991 | 685 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 152 | 0.030 |
Why?
|
| Esophagus | 1 | 2015 | 102 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2015 | 80 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1996 | 369 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 187 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2006 | 1565 | 0.030 |
Why?
|
| Sepsis | 1 | 1998 | 306 | 0.030 |
Why?
|
| L-Selectin | 2 | 2005 | 16 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 274 | 0.030 |
Why?
|
| Models, Immunological | 1 | 1995 | 80 | 0.030 |
Why?
|
| Health Policy | 1 | 1996 | 180 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2014 | 69 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 159 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2006 | 78 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2006 | 39 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 64 | 0.030 |
Why?
|
| Drug Synergism | 4 | 1998 | 303 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 34 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 369 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 1995 | 150 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1994 | 84 | 0.030 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 244 | 0.030 |
Why?
|
| Toll-Like Receptors | 2 | 2006 | 92 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2004 | 66 | 0.030 |
Why?
|
| Tremor | 1 | 1994 | 22 | 0.030 |
Why?
|
| Body Composition | 1 | 2014 | 68 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 692 | 0.030 |
Why?
|
| Biological Factors | 1 | 1993 | 18 | 0.030 |
Why?
|
| Hemofiltration | 1 | 1993 | 11 | 0.030 |
Why?
|
| Prisoners | 1 | 2014 | 40 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Survivors | 2 | 2007 | 226 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 1994 | 54 | 0.030 |
Why?
|
| Danazol | 1 | 1993 | 2 | 0.030 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1993 | 19 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 1997 | 346 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 289 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 2 | 2004 | 10 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 48 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 307 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 1991 | 38 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2014 | 129 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 560 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 121 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 394 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 113 | 0.030 |
Why?
|
| Fatigue | 1 | 1994 | 174 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 214 | 0.030 |
Why?
|
| Transduction, Genetic | 2 | 2003 | 153 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 462 | 0.030 |
Why?
|
| HLA-DQ Antigens | 3 | 2005 | 52 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 696 | 0.030 |
Why?
|
| Kinetics | 4 | 2000 | 1513 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2005 | 1169 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 20 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2000 | 1041 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1992 | 60 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2012 | 46 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 262 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 1995 | 298 | 0.030 |
Why?
|
| Pyoderma | 1 | 1991 | 3 | 0.030 |
Why?
|
| Principle-Based Ethics | 1 | 2011 | 4 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2007 | 459 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1991 | 20 | 0.030 |
Why?
|
| Radiography, Abdominal | 2 | 2004 | 71 | 0.030 |
Why?
|
| Therapeutic Irrigation | 3 | 1987 | 60 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2011 | 15 | 0.030 |
Why?
|
| Keratitis | 1 | 1991 | 22 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 273 | 0.030 |
Why?
|
| Vestibular Diseases | 1 | 1991 | 27 | 0.030 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 173 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1991 | 61 | 0.030 |
Why?
|
| Coculture Techniques | 2 | 2002 | 164 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 130 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 1128 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2001 | 137 | 0.030 |
Why?
|
| Blood Circulation | 1 | 1991 | 29 | 0.030 |
Why?
|
| Monitoring, Physiologic | 3 | 1998 | 268 | 0.020 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 96 | 0.020 |
Why?
|
| Hemagglutination Tests | 1 | 1990 | 11 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 39 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2010 | 10 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 449 | 0.020 |
Why?
|
| Cattle | 2 | 2001 | 376 | 0.020 |
Why?
|
| CHO Cells | 2 | 2001 | 187 | 0.020 |
Why?
|
| CD59 Antigens | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2010 | 39 | 0.020 |
Why?
|
| CD55 Antigens | 1 | 2010 | 20 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 849 | 0.020 |
Why?
|
| Animals, Outbred Strains | 1 | 2010 | 15 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 421 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 169 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 468 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 144 | 0.020 |
Why?
|
| Glycogen | 1 | 2010 | 59 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1990 | 141 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1997 | 878 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 1997 | 989 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 592 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 332 | 0.020 |
Why?
|
| Immunocompromised Host | 2 | 2004 | 140 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1990 | 290 | 0.020 |
Why?
|
| Capsule Endoscopy | 1 | 2009 | 33 | 0.020 |
Why?
|
| Codes of Ethics | 1 | 2009 | 12 | 0.020 |
Why?
|
| Policy Making | 2 | 2001 | 62 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 1990 | 75 | 0.020 |
Why?
|
| Exons | 2 | 2001 | 450 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2271 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2001 | 393 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 124 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 2000 | 1135 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 1999 | 71 | 0.020 |
Why?
|
| Altruism | 1 | 2009 | 35 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1990 | 63 | 0.020 |
Why?
|
| Crime | 1 | 2009 | 36 | 0.020 |
Why?
|
| Motivation | 1 | 2011 | 287 | 0.020 |
Why?
|
| Mice, Inbred DBA | 2 | 1999 | 148 | 0.020 |
Why?
|
| Ligands | 2 | 2001 | 433 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 88 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1988 | 20 | 0.020 |
Why?
|
| Ganciclovir | 2 | 1999 | 49 | 0.020 |
Why?
|
| Immunoelectrophoresis | 2 | 2000 | 19 | 0.020 |
Why?
|
| Brain | 1 | 1998 | 2216 | 0.020 |
Why?
|
| Rats, Inbred F344 | 3 | 1993 | 156 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 297 | 0.020 |
Why?
|
| Phytohemagglutinins | 2 | 2003 | 22 | 0.020 |
Why?
|
| Viremia | 2 | 2000 | 54 | 0.020 |
Why?
|
| Hyponatremia | 1 | 2008 | 25 | 0.020 |
Why?
|
| Species Specificity | 3 | 1994 | 678 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 937 | 0.020 |
Why?
|
| Alcoholism | 2 | 2001 | 172 | 0.020 |
Why?
|
| Complement Inactivator Proteins | 2 | 2000 | 27 | 0.020 |
Why?
|
| Life Style | 1 | 2008 | 189 | 0.020 |
Why?
|
| Colon | 3 | 2000 | 496 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 312 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 363 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 44 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 2062 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2006 | 36 | 0.020 |
Why?
|
| Carcinoma | 1 | 2010 | 436 | 0.020 |
Why?
|
| Biological Assay | 1 | 2006 | 78 | 0.020 |
Why?
|
| Biological Therapy | 1 | 2007 | 45 | 0.020 |
Why?
|
| Peyer's Patches | 2 | 2000 | 18 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2007 | 123 | 0.020 |
Why?
|
| CD3 Complex | 2 | 1998 | 135 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1993 | 503 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1999 | 100 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2000 | 316 | 0.020 |
Why?
|
| H-2 Antigens | 2 | 1999 | 58 | 0.020 |
Why?
|
| Plasmids | 1 | 2006 | 287 | 0.020 |
Why?
|
| Contraindications | 1 | 2006 | 72 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 1998 | 307 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2006 | 188 | 0.020 |
Why?
|
| CD52 Antigen | 1 | 2005 | 3 | 0.020 |
Why?
|
| Cautery | 1 | 2004 | 2 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 75 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2005 | 143 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1997 | 69 | 0.020 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2004 | 1 | 0.020 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2005 | 115 | 0.020 |
Why?
|
| Metronidazole | 1 | 2004 | 26 | 0.020 |
Why?
|
| DNA Primers | 2 | 1995 | 543 | 0.020 |
Why?
|
| Remission Induction | 2 | 1998 | 722 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 2 | 1995 | 87 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2003 | 19 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2004 | 57 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2003 | 49 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 72 | 0.010 |
Why?
|
| HLA-B Antigens | 2 | 1997 | 35 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 72 | 0.010 |
Why?
|
| HLA-A Antigens | 2 | 1997 | 44 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2003 | 44 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 2 | 1995 | 16 | 0.010 |
Why?
|
| Flucytosine | 1 | 2003 | 11 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 89 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 50 | 0.010 |
Why?
|
| Dependovirus | 1 | 2003 | 33 | 0.010 |
Why?
|
| Digestive System | 2 | 1997 | 42 | 0.010 |
Why?
|
| Hyperglycemia | 2 | 1996 | 176 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2003 | 59 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2003 | 81 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 41 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 23 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 50 | 0.010 |
Why?
|
| Cell Aggregation | 2 | 1992 | 39 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 348 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 65 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 231 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2002 | 33 | 0.010 |
Why?
|
| Pongo pygmaeus | 1 | 2001 | 10 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 132 | 0.010 |
Why?
|
| Cercopithecidae | 1 | 2001 | 13 | 0.010 |
Why?
|
| Atrophy | 1 | 2002 | 117 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2002 | 157 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 180 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 224 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2001 | 25 | 0.010 |
Why?
|
| Calcimycin | 2 | 1993 | 33 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 118 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 256 | 0.010 |
Why?
|
| Italy | 1 | 2001 | 106 | 0.010 |
Why?
|
| Lipids | 1 | 2003 | 269 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2001 | 20 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 117 | 0.010 |
Why?
|
| Plasma | 1 | 2001 | 50 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2001 | 82 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 146 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2001 | 24 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2002 | 140 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 179 | 0.010 |
Why?
|
| International Cooperation | 1 | 2001 | 127 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2002 | 106 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 42 | 0.010 |
Why?
|
| Omentum | 2 | 1992 | 71 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 102 | 0.010 |
Why?
|
| Surgical Sponges | 1 | 2001 | 3 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 416 | 0.010 |
Why?
|
| Cyclins | 1 | 2001 | 82 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 74 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 117 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 41 | 0.010 |
Why?
|
| Uric Acid | 2 | 1991 | 139 | 0.010 |
Why?
|
| Elapid Venoms | 1 | 2000 | 5 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2000 | 17 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2000 | 53 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2000 | 50 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2001 | 94 | 0.010 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2000 | 6 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2001 | 132 | 0.010 |
Why?
|
| Ligation | 1 | 2000 | 51 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1992 | 790 | 0.010 |
Why?
|
| HLA-DP Antigens | 2 | 1991 | 9 | 0.010 |
Why?
|
| Dextrans | 1 | 1980 | 77 | 0.010 |
Why?
|
| Phosphorylcholine | 1 | 1980 | 28 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 106 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 229 | 0.010 |
Why?
|
| Collagen | 1 | 2001 | 269 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 289 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2000 | 271 | 0.010 |
Why?
|
| Bacteremia | 1 | 2000 | 99 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2000 | 188 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1999 | 36 | 0.010 |
Why?
|
| Lung | 1 | 1986 | 1170 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 646 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 49 | 0.010 |
Why?
|
| Influenza Vaccines | 1 | 2000 | 142 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 188 | 0.010 |
Why?
|
| Constriction | 1 | 1999 | 27 | 0.010 |
Why?
|
| Internet | 1 | 2001 | 312 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 493 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 504 | 0.010 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 1998 | 3 | 0.010 |
Why?
|
| Hepatitis, Animal | 1 | 1998 | 2 | 0.010 |
Why?
|
| fas Receptor | 1 | 1999 | 75 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 1998 | 15 | 0.010 |
Why?
|
| Lac Operon | 1 | 1998 | 46 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1998 | 23 | 0.010 |
Why?
|
| Equipment and Supplies | 1 | 1999 | 30 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1998 | 5 | 0.010 |
Why?
|
| Genome, Viral | 1 | 1999 | 74 | 0.010 |
Why?
|
| Body Constitution | 1 | 1998 | 26 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1999 | 121 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1998 | 32 | 0.010 |
Why?
|
| Self-Assessment | 1 | 1998 | 47 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 1998 | 8 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 372 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 1998 | 71 | 0.010 |
Why?
|
| Point Mutation | 1 | 1999 | 246 | 0.010 |
Why?
|
| Cost Savings | 1 | 1998 | 66 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1998 | 16 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1999 | 268 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1998 | 42 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 98 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 1997 | 3 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 88 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1998 | 96 | 0.010 |
Why?
|
| Medical Records | 1 | 1998 | 119 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 1998 | 116 | 0.010 |
Why?
|
| Venules | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1997 | 106 | 0.010 |
Why?
|
| Research Design | 1 | 2001 | 594 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1621 | 0.010 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 1997 | 3 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1998 | 80 | 0.010 |
Why?
|
| Federal Government | 1 | 1997 | 29 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1998 | 157 | 0.010 |
Why?
|
| Sex Determination Analysis | 1 | 1997 | 18 | 0.010 |
Why?
|
| Milk, Human | 1 | 1997 | 43 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1997 | 116 | 0.010 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1997 | 16 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2001 | 853 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 63 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 1998 | 103 | 0.010 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 1997 | 9 | 0.010 |
Why?
|
| Heart Valves | 1 | 1997 | 13 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1997 | 90 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1997 | 91 | 0.010 |
Why?
|
| Blood | 1 | 1997 | 69 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 1997 | 33 | 0.010 |
Why?
|
| Genome, Human | 1 | 2001 | 756 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 63 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 227 | 0.010 |
Why?
|
| Jejunum | 1 | 1997 | 79 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 1997 | 34 | 0.010 |
Why?
|
| Phosphatidic Acids | 1 | 1996 | 4 | 0.010 |
Why?
|
| Rats, Gunn | 1 | 1996 | 2 | 0.010 |
Why?
|
| Phylogeny | 1 | 2001 | 1137 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 926 | 0.010 |
Why?
|
| Pharynx | 1 | 1996 | 45 | 0.010 |
Why?
|
| Virus Shedding | 1 | 1996 | 26 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1996 | 129 | 0.010 |
Why?
|
| Anxiety | 1 | 1998 | 287 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 68 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1997 | 160 | 0.010 |
Why?
|
| Mercuric Chloride | 1 | 1996 | 8 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1998 | 751 | 0.010 |
Why?
|
| Interferons | 1 | 1996 | 133 | 0.010 |
Why?
|
| Placenta | 1 | 1997 | 175 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1997 | 244 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1995 | 56 | 0.010 |
Why?
|
| Laminin | 1 | 1996 | 85 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1998 | 325 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1997 | 261 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1995 | 20 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1995 | 14 | 0.010 |
Why?
|
| Veins | 1 | 1995 | 94 | 0.010 |
Why?
|
| Amylases | 1 | 1995 | 13 | 0.010 |
Why?
|
| Capillaries | 1 | 1995 | 91 | 0.010 |
Why?
|
| Warts | 1 | 1995 | 11 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1996 | 233 | 0.010 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1995 | 6 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1995 | 30 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1995 | 92 | 0.010 |
Why?
|
| Cell Lineage | 1 | 1996 | 273 | 0.010 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 1 | 1994 | 3 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1995 | 60 | 0.010 |
Why?
|
| Arteries | 1 | 1995 | 176 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1994 | 74 | 0.010 |
Why?
|
| Boston | 1 | 1994 | 33 | 0.010 |
Why?
|
| Weight Loss | 1 | 1996 | 229 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 1998 | 398 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 80 | 0.010 |
Why?
|
| Heart | 1 | 1997 | 539 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 129 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 1993 | 5 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1993 | 20 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 376 | 0.010 |
Why?
|
| Phosphonoacetic Acid | 1 | 1993 | 1 | 0.010 |
Why?
|
| Xylose | 1 | 1993 | 23 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1993 | 19 | 0.010 |
Why?
|
| Family | 1 | 1995 | 311 | 0.010 |
Why?
|
| Growth | 1 | 1993 | 43 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1993 | 64 | 0.010 |
Why?
|
| Ribonucleosides | 1 | 1993 | 25 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1993 | 60 | 0.010 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1995 | 190 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 177 | 0.010 |
Why?
|
| Polyvinyl Chloride | 1 | 1992 | 8 | 0.010 |
Why?
|
| Arthritis, Psoriatic | 1 | 1992 | 32 | 0.010 |
Why?
|
| Drug Packaging | 1 | 1992 | 7 | 0.010 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 1991 | 5 | 0.010 |
Why?
|
| Glass | 1 | 1992 | 15 | 0.010 |
Why?
|
| Syringes | 1 | 1992 | 13 | 0.010 |
Why?
|
| Weight Gain | 1 | 1993 | 123 | 0.010 |
Why?
|
| Drug Stability | 1 | 1992 | 48 | 0.010 |
Why?
|
| Adsorption | 1 | 1992 | 54 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1991 | 62 | 0.010 |
Why?
|
| Nephrotic Syndrome | 1 | 1991 | 33 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1991 | 25 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1992 | 88 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1997 | 760 | 0.010 |
Why?
|
| Adenoma, Bile Duct | 1 | 1991 | 4 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1991 | 20 | 0.010 |
Why?
|
| Minor Histocompatibility Loci | 1 | 1991 | 1 | 0.010 |
Why?
|
| Amino Acid Isomerases | 1 | 1991 | 5 | 0.010 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 1991 | 8 | 0.010 |
Why?
|
| Methods | 1 | 1991 | 152 | 0.010 |
Why?
|
| Magnesium | 1 | 1991 | 177 | 0.010 |
Why?
|
| Jaundice | 1 | 1991 | 14 | 0.010 |
Why?
|
| Blood Group Antigens | 1 | 1991 | 17 | 0.010 |
Why?
|
| Mesentery | 1 | 1991 | 45 | 0.010 |
Why?
|
| Stents | 1 | 1994 | 377 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1991 | 165 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 3968 | 0.010 |
Why?
|
| Wound Infection | 1 | 1990 | 17 | 0.010 |
Why?
|
| Haplotypes | 1 | 1992 | 642 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1990 | 258 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1993 | 355 | 0.010 |
Why?
|
| Biological Availability | 1 | 1990 | 92 | 0.010 |
Why?
|
| Mitosis | 1 | 1990 | 153 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2001 | 1721 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1990 | 256 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1995 | 645 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1993 | 521 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1988 | 27 | 0.010 |
Why?
|
| Factor VIII | 1 | 1988 | 7 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1988 | 42 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1988 | 31 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1988 | 37 | 0.010 |
Why?
|
| Culture Media | 1 | 1988 | 147 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 827 | 0.000 |
Why?
|
| Sleep | 1 | 1991 | 444 | 0.000 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1987 | 18 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1987 | 220 | 0.000 |
Why?
|
| Heart Diseases | 1 | 1987 | 290 | 0.000 |
Why?
|